Whitepapers/App Notes/Posters

Application note: Industry pushes back on USP draft chapter

Posted: 15 February 2021 | | No comments yet

Outlining the most common comments from drug manufacturers, the Parenteral Drug Association (PDA) and US Food and Drug Administration (FDA) on the USP draft chapter for recombinant Factor C (<1085.1>).

The USP Draft chapter for recombinant Factor C (<1085.1>) put forward by USP experts for industry comment, which ended in November 2020, included specific points that brought detailed replies shared among drug manufacturers, the Parenteral Drug Association (PDA) and US Food and Drug Administration (FDA). The most common comments among drug companies, the PDA and FDA are outlined here. Of note, the recombinant Factor C test (2.6.32) became an official compendial test in the EU on 1 January 2021, while similar efforts are underway in Japan and China. As a compendial test, Ph. Eur. 2.6.32 does not require the alternative validation that USP draft chapter <1085.1> seeks to enact in the non-binding chapter <1085>.












    To read this application note in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of bioMérieux

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend